Article and Video CATEGORIES
We'll kick off our monthly live webinar series, co-sponsored by GRACE along with LUNGevity Foundation, with our annual "Highlights in Lung Cancer" program. This one, featuring the leading developments from 2012, will be by Dr. Natasha Leighl, medical oncologist and lung cancer expert at Princess Margaret Hospital, as well as Assistant Professor of Medicine at the University of Toronto in Ontario, Canada. Dr. Leighl has been an internationally recognized leader in thoracic oncology and also a friend of mine for more than a decade. She's also been a friend and fan of GRACE, but we haven't reached out to her enough, so it's only fitting that we rectify that by having her provide her wonderful perspective for our Lung Cancer Highlights program.
This program will be on January 17th at 7 PM Eastern, 4 PM Pacific time, when Dr. Leighl will cover topics ranging from immunotherapy to new targets and potential targeted therapies, as well as newly identified mechanisms of acquired resistance and potential strategies for addressing this.
We'll turn her presentation into a series f free podcasts to be released on the GRACE and LUNGevity websites, but you can learn the key points first and even ask your own live questions after her live presentation. So please join us on January 17th! As always, it's free, and you can sign up through this link.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…